在新辅助剂治疗的乳腺癌中进行个性化多因素风险评估
K Korpinen1, T A Autere2, J Tuominen3
1Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10/MedD5A, 20500, Turku, Finland. kkhkor@utu.fi.
Breast cancer research and treatment
|December 31, 2024
概括
预测乳腺癌对新辅助治疗 (NAT) 的反应是复杂的. 这项研究确定了临床和组织学因素,以改善结果,并为接受NAT的乳腺癌患者个性化后续治疗.
科学领域:
- 在瘤学瘤学.
- 病理学 病理学 病理学
- 遗传学 是一个遗传学.
背景情况:
- 乳腺癌表现出显著的生物学异质性,使对新辅助治疗 (NAT) 个体反应的预测变得复杂.
- 由于这种复杂性,目前的治疗后跟踪策略缺乏全面的,普遍接受的指导方针.
研究的目的:
- 开发和提出临床和组织病理学标准,以便在接受NAT的乳腺癌患者中更好地预测疾病结果.
- 在NAT之后推进个性化治疗策略和风险适应的监测.
主要方法:
- 对257名芬兰乳腺癌患者接受NAT治疗的回顾性分析,随访时间长达13年.
- 对预后影响的NAT前后组织样本 (乳腺和转移) 的评估.
- 在统计分析中包括与NAT反应,疾病过程和患者结局相关的临床和生物标志物特征.
主要成果:
- 确定了关键的预后因素,包括线粒体和质活动,并强调了降低孕激素受体 (PR) 水平的重要性.
- 降低PR与3.8倍的死亡风险增加和显著更短的存活时间有关.
- 开发了热图和交互工具 (bcnatreccalc.utu.fi),以根据已识别的预后因素量化死亡率和复发风险.
结论:
- 强调对常规患者和生物标志物特征进行全面评估的重要性,包括NAT后的再评估.
- 倡导基于综合评估的风险调整监测和个性化治疗策略.
- 建议未来的个性化NAT策略可以将风险适应的监测数据与NAT后生物标志物重新评估相结合.
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
01:21Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328